- Home
- RIVN vs RPRX Comparison
RIVN vs RPRX Comparison
Compare RIVN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- RPRX
- Stock Information
- Founded
- RIVN 2009
- RPRX 1996
- Country
- RIVN United States
- RPRX United States
- Employees
- RIVN N/A
- RPRX N/A
- Industry
- RIVN Auto Manufacturing
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RIVN Consumer Discretionary
- RPRX Health Care
- Exchange
- RIVN Nasdaq
- RPRX Nasdaq
- Market Cap
- RIVN 15.0B
- RPRX 14.2B
- IPO Year
- RIVN 2021
- RPRX 2020
- Fundamental
- Price
- RIVN $11.60
- RPRX $32.60
- Analyst Decision
- RIVN Hold
- RPRX Strong Buy
- Analyst Count
- RIVN 21
- RPRX 4
- Target Price
- RIVN $13.85
- RPRX $42.50
- AVG Volume (30 Days)
- RIVN 34.6M
- RPRX 5.5M
- Earning Date
- RIVN 05-06-2025
- RPRX 05-08-2025
- Dividend Yield
- RIVN N/A
- RPRX 2.71%
- EPS Growth
- RIVN N/A
- RPRX N/A
- EPS
- RIVN N/A
- RPRX 1.91
- Revenue
- RIVN $4,970,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- RIVN $12.96
- RPRX $31.56
- Revenue Next Year
- RIVN $38.21
- RPRX $5.94
- P/E Ratio
- RIVN N/A
- RPRX $17.05
- Revenue Growth
- RIVN 12.09
- RPRX N/A
- 52 Week Low
- RIVN $8.32
- RPRX $24.05
- 52 Week High
- RIVN $18.86
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- RIVN 48.35
- RPRX 54.58
- Support Level
- RIVN $11.17
- RPRX $32.02
- Resistance Level
- RIVN $12.15
- RPRX $32.31
- Average True Range (ATR)
- RIVN 0.92
- RPRX 0.97
- MACD
- RIVN -0.01
- RPRX 0.12
- Stochastic Oscillator
- RIVN 39.62
- RPRX 97.84
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.